Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October
ProQR’s failed divestiture: Laboratoires Théa scrapped plans to buy ProQR Therapeutics’ late-stage ophthalmic pipeline after announcing a deal in early August for €147.5 million, or about $162 million. On Wednesday, ProQR said some of its ophthalmology workers decided not to join the new company, and as a result, Théa terminated the deal. — Jaimy Lee
Immunovant’s $130 million offering: Immunovant’s early-stage autoimmune data, viewed by analysts as a potential catalyst for a sale or other transaction, spurred a major financing haul for the New York biotech. It presented data on its anti-FcRn IMVT-1402 Tuesday morning. Later that day, it disclosed plans for a $130 million public offering and a $170 million boost from its parent, Roivant Sciences. — Kyle LaHucik
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
